## BEAM: Beam Therapeutics Inc. - XLV: Healthcare

### Executive Summary

PARABOLIC warning: MRS_20 at 10.5% exceeds exhaustion threshold (10.0%). Extreme momentum typically precedes mean reversion. Consider profit-taking or tight stops. Caution: momentum weakening (-1.9% MRS).

- **Horizon:** 1-5 days (momentum)
- **Risk Profile:** High - extreme momentum reversal risk
- **Stop Type:** Fixed 2xATR ($23.98)
- **If Wrong:** Exit on momentum reversal or stop hit
- **Invalidation:** MRS_20 drops below exhaustion threshold

### News

- **Articles:** 2
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Efficient Sickle Cell Base-Editing Data Might Change The Case For Investing In Beam Therapeutics (BEAM)**
- Source: Simply Wall Street | 20251211T180904 | Bullish | Relevance: 100%
- Beam Therapeutics has released promising Phase 1/2 BEACON trial data for its sickle cell therapy, risto-cel, showing efficient cell collection and sustained increases in protective hemoglobin F. These results may strengthen the investment narrative by confirming biological activity and manufacturing consistency, though challenges regarding conditioning toxicity and the path to commercialization remain. The company also secured a $500M equity raise, signaling its commitment to development despite unprofitability and early trial stages.

**2. Nikko Asset Management Americas Inc. Increases Stock Holdings in Beam Therapeutics Inc. $BEAM**
- Source: MarketBeat | 20251214T110934 | Somewhat-Bullish | Relevance: 100%
- Nikko Asset Management Americas Inc. significantly increased its stake in Beam Therapeutics Inc. by 10.7% in Q2, raising its holdings to 4,726,799 shares valued at approximately $80.4 million. Despite recent misses on EPS and revenue estimates, analysts maintain a "Moderate Buy" rating for Beam Therapeutics with an average price target of $45.58. The company is actively developing precision genetic medicines, including treatments for sickle cell disease and alpha-1 antitrypsin deficiency.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-24 | Evercore ISI Gr | $35 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-24 | Evercore ISI Gr | init | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 1 ($0.02M) |
| Sells | 5 ($0.65M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 70.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 2 |

**Top Holders:**
- FMR, LLC: 11.5% (-9.8%)
- ARK Investment Manag: 10.9% (+24.8%)
- Farallon Capital Man: 9.9% (+0.5%)
- Vanguard Group Inc: 9.1% (-4.7%)
- Blackrock Inc.: 8.0% (+1.8%)

### Key Risks

1. High beta (2.22) amplifies market volatility - any risk-off move could trigger sharp selloff.
2. Valuation stretched: PEG 7.1x requires aggressive growth execution.
3. High short interest (23.2%, 9.3 days to cover): squeeze risk or crowded bearish bet.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 7.09 signals overvaluation risk, limited margin of safety. Balance sheet: strong liquidity (6.0x), low leverage (D/E 0.36). Institutional flow bullish (6 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $2.8B |
| Beta | 2.22 |
| 52W Range | $13.53 - $35.25 |
| Short Interest | 23.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 7.09 |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_20 deteriorating from 12.4% to 10.5% (-1.9% in 5 days), indicating relative weakness vs NASDAQ. Extended beyond STRENGTH zone (10.5% > 10.0%), caution on chasing. MRS_5 at 2.1% confirms short-term momentum alignment. AM_20 at 10.7% shows strong absolute momentum above own 20MA. Outperforming sector by 10.8pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 59. OFD pattern: -SLL (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 10.49% (CS: 95) | Strong |
| RSI_14 | 59.3 | Neutral |
| MACD Histogram | 0.36 | Bullish |
| vs SMA20 | 1.107x | Above |
| vs SMA50 | 1.089x | Above |
| vs SMA200 | 1.304x | Above |

### Decision

- **Verdict:** SELL
- **Thesis:** PARABOLIC

### Trade Setup

- **Entry:** $27.36
- **Stop Loss:** $23.98 (12.4% risk)
- **Target:** $30.74 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** PARABOLIC thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 295
- **Position Value:** $8,071.20
- **Portfolio %:** 8.07%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX remains calm at 15.74 while breadth shows modest participation at 54%, suggesting selective positioning. FOMC meeting in 4 days creates near-term uncertainty but no systemic stress evident.*

### Earnings

**Next:** 2026-02-24 (Est: $-1.12)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-1.01 | $-1.10 | -8.9% |
| 2025Q2 | $-1.09 | $-1.00 | +8.4% |
| 2025Q1 | $-1.17 | $-1.24 | -5.9% |
| 2024Q4 | $-1.22 | $-1.09 | +10.3% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*